Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Bandaru, Nagaraju
- Neuroprotective Effects of Isolated Fraction from Sapindus laurifolia Extract in Hippocampal Neuronal HT22 Cells
Abstract Views :244 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutical Sciences, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram – 522019, Guntur, Andhra Pradesh, IN
1 Department of Pharmaceutical Sciences, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram – 522019, Guntur, Andhra Pradesh, IN
Source
Toxicology International (Formerly Indian Journal of Toxicology), Vol 27, No 1&2 (2020), Pagination: 79-85Abstract
Glutamate is a major endogenous excitatory neurotransmitter in the brain and contributes to the development of neurodegenerative diseases by excessive activation. The purpose of the present study was to determine the neuroprotective effect of Sapindus laurifolia (MESL) Fraction A against glutamate-induced oxidative stress and to assess the underlying mechanism. MESL Fraction A was subjected to a neuroprotective effect assay in HT22 mouse hippocampal cells. The mechanism underlying the neuroprotective effect of MESL Fraction A was evaluated by assaying Reactive Oxygen Species (ROS) levels, intracellular Ca2+ levels, mitochondrial membrane potential and glutathione level and antioxidant enzyme activity in HT22 cells. MESL Fraction A significantly decreased glutamate-induced death of HT22 cells (88.23 ± 1.65% relative neuroprotection). MESL Fraction A reduced the intracellular ROS and Ca2+ levels and increased the glutathione level and glutathione reductase and glutathione peroxide activities. Moreover, MESL Fraction A attenuated the mitochondrial membrane potential in HT22 cells. These results suggested that MESL Fraction A exerts a neuroprotective effect against oxidative stress HT22 cells, which was mediated by its antioxidant activity.Keywords
Antioxidant, Glutamate, Hippocampal Cells, Neuroprotective, Oxidative Stress.References
- Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int. 2004 Oct; 45(5):583–95. PMid: 15234100. https://doi.org/10.1016/j.neuint.2004.03.007
- Choi DW. Glutamate neurotoxicity in cortical cell cultures is calcium dependent. Neurosci. Lett. 1985; 58(3):293–7. https://doi.org/10.1016/0304-3940(85)90069-2
- Tan S, Wood M, Maher P. Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. J Neurochem. 1998 Jul; 71(1):95–105. PMid: 9648855. https://doi. org/10.1046/j.1471-4159.1998.71010095.x
- Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT. Glutamate toxicity in neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 1989; 2(6):1547–58. https://doi.org/10.1016/0896- 6273(89)90043-3
- Swerdlow RH. Pathogenesis of Alzheimer’s disease. Clin Interv Aging, 2007; 2(3):347–59.
- Liu J, Li L, Suo WZ. HT22 hippocampal neuronal cell line possesses functional cholinergic properties. Life Sci. 2009 Feb; 84(9-10):267–71. PMid: 19135458. https://doi. org/10.1016/j.lfs.2008.12.008
- Sakthivel KM, Guruvayoorappan C. Biophytum sensitivum, ancient medicine, modern targets. J Adv Pharm Technol Res. 2012; (3): 83–91. PMid: 22837955 PMCid: PMC3401679. https://doi.org/10.4103/2231-4040.97279
- Trease G, Evans SM. Pharmacognosy. 15th ed. London: Bailer Tindal; 2002. p. 23–67.
- Yun BR, Yang HJ, Weon JB, Lee J, Eom MR, Ma CJ. Neuroprotective properties of compounds extracted from Dianthus superbus L. against glutamate-induced cell death in HT22 cells. Pharmacogn Mag. 2016 Apr-Jun; 12(46):109–13. PMid: 27076746 PMCid: PMC4809164. https://doi.org/10.4103/0973-1296.177905
- Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 1997; 23(1):134–47. https:// doi.org/10.1016/S0891-5849(96)00629-6
- Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P, et al. Glutamateinduced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. Neuron.1995; 15(4):961–73. https://doi.org/10.1016/0896- 6273(95)90186-8
- Duchen M. Mitochondria and calcium: From cell signaling to cell death. J Physiol. 2000; 529(11):57–68. PMid: 11080251 PMCid: PMC2270168. https://doi.org/10.1111/ j.1469-7793.2000.00057.x
- Reynolds IJ, Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci. 1995; 15:3318–27. PMid: 7751912 PMCid: PMC6578215. https://doi.org/10.1523/JNEUROSCI.15-05-03318.1995
- Randall RD, Tayer SA. Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons. J Neurosci. 1992; 12(5):1882–95. PMid: 1349638 PMCid: PMC6575874. https://doi. org/10.1523/JNEUROSCI.12-05-01882.1992
- Koga M, Serritella AV, Messmer MM, Hayashi-Takagi A, Hester LD, Snyder SH, Sawa A, Sedlak TW. Glutathione is a physiologic reservoir of neuronal glutamate. Biochem Biophys Res Commun. 2011; 409(4):596–602. PMid: 21539809 PMCid: PMC3923312. https://doi.org/10.1016/j. bbrc.2011.04.087
- Ly JD, Grubb DR, Lawen A. Mitochondrial membrane potential (ψ) in apoptosis; an update. Apoptosis. 2003 Mar; 8(2):115–28. PMid: 12766472. https://doi. org/10.1023/A:1022945107762
- Overview on Alzheimer’s Disease
Abstract Views :86 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram – 522502, Andhra Pradesh, IN
1 Department of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram – 522502, Andhra Pradesh, IN
Source
Toxicology International (Formerly Indian Journal of Toxicology), Vol 28, No 4 (2021), Pagination: 311-316Abstract
The world wide spread dementia of Alzeheimer disease is estimated to be as high as 24 million and it is hypothesized to be double every 20 years through 2040 resulting to a costly risk of the disease. Alzehimer disease is the main cause of dementia and is manifested by a gradual loss of cognitive function which is initially begin with deterioration of memory. Before death, the patient is fully dependent on their care givers. The main mechanism underlying the neuropath logical changes in Alzheimer patient are remaining unknown. But mainly they may be affected by both environmental and genetic factors. The hall mark pathology of Alzheimer disease are mainly accompanied by the presence of reactive microgliosis and the loss of neurons, white matter and synapses3 .Keywords
Dementia, Deterioration of Memory, Loss of Cognitive Function, Reactive Microgliosis, Synapses, White MatterReferences
- Smith MA. Alzheimer disease. Int Rev Neurobiol. 1998; 42:1– 54. https://doi.org/10.1016/S0074-7742(08)60607-8.
- Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287(18):2335–8. https://doi.org/10.1001/jama.287.18.2335. PMid:11988038.
- Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. 1991; 82(4):239–59. https://doi.org/10.1007/BF00308809. PMid:1759558.
- Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7(3):137–52. https:// doi.org/10.1038/nrneurol.2011.2. PMid:21304480. PMCid:PMC3339565.
- Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287(18):2335–8. https://doi.org/10.1001/jama.287.18.2335. PMid:11988038.
- Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012; 148(6):1204–22. https:// doi.org/10.1016/j.cell.2012.02.040. PMid:22424230. PMCid:PMC3319071.
- Winslow BT, Onysko M, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011; 83(12):1403–12.
- Batsch NL, Mittelman MS. World Alzheimer Report 2012. Overcoming the Stigma of Dementia. Alzheimer’s Disease INTERNATIONAL (ADI), London; 2012.
- Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013; 368(2):107–16.
- Knuesel I, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol. 2014; 10(11):643. https://doi.org/10.1038/nrneurol.2014.187. PMid:25311587.
- Krstic D, Knuesel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013; 9(1):25. https://doi.org/10.1038/nrneurol.2012.236. PMid:23183882.
- Sosa-Ortiz, AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res. 2012; 43(8):600–8. https://doi.org/10.1016/j.arcmed.2012.11.003. PMid:23159715.
- Bonda DJ, et al. Role of metal dyshomeostasis in Alzheimer’s disease. Metallomics. 2011; 3(3): 267–70. https://doi.org/10.1039/c0mt00074d. PMid:21298161. PMCid:PMC3117398.
- Van Gorp B, Vercruysse T. Frames and counter-frames giving meaning to dementia: A framing analysis of media content. Soc Sci Med. 2012; 74(8):1274–81. https://doi. org/10.1016/j.socscimed.2011.12.045. PMid:22386639.
- Melo A, et al. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid Med Cell Longev. 2011. https://doi.org/10.1155/2011/467180. PMid:22191013. PMCid:PMC3236428.
- Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr. 2000; 71(2):621S–9S. https://doi.org/10.1093/ ajcn/71.2.621s. PMid:10681270.
- Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science. 2001; 293(5534):1449–54. https://doi.org/10.1126/science.1064638. PMid:11520976.
- Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999; 13:S106–14. https://doi.org/10.1097/00002093-199912003- 00016. PMid:10609689.
- Larson EB, et al. Survival after initial diagnosis of Alzheimer disease. Annals of internal medicine. 2004; 140(7):501–9. https://doi.org/10.7326/0003-4819-140-7- 200404060-00008. PMid:15068977.
- Engelhart MJ, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002; 287(24):3223–29. https:// doi.org/10.1001/jama.287.24.3223. PMid:12076218.
- De la Torre JC. Alzheimer disease as a vascular disorder: Nosological Evidence. Stroke. 2002; 33(4):1152–62. https://doi.org/10.1161/01.STR.0000014421.15948.67. PMid:11935076.
- Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer’s disease. N Engl J Med. 2013; 368(13):1169–71. https://doi.org/10.1056/ NEJMp1302513. PMid:23484795.
- Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Medicine. 2009; 7(1):1–4. https://doi.org/10.1186/1741-7015-7-7. PMid:19228370. PMCid:PMC2649159.
- Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother. 1994; 28(6):744–51. https:// doi.org/10.1177/106002809402800612. PMid:7919566.
- Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med. 1999; 341(22):1670–79. https://doi.org/10.1056/ NEJM199911253412207. PMid:10572156.
- Molinuevo J L, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018; 136(6):821–53. https:// doi.org/10.1007/s00401-018-1932-x. PMid:30488277. PMCid:PMC6280827.
- Behrens S, et al. Use of FDA approved medications for Alzheimer’s disease in mild dementia is associated with reduced informal costs of care. Int Psychogeriatr. 2018; 30(10):1499. https://doi.org/10.1017/S104161021800011X. PMid:29559029. PMCid:PMC6150839.
- Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2010; 11(10):1765– 71. https://doi.org/10.1517/14656566.2010.493874. PMid:20540654.
- Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med. 2006; 57:513–33. https://doi.org/10.1146/annurev. med.57.121304.131442. PMid:16409164.
- Romero K, et al. The future is now: model‐based clinical trial design for Alzheimer’s disease. Clin Pharmacol Ther. 2015; 97(3):210–14. https://doi.org/10.1002/cpt.16. PMid:25669145. PMCid:PMC6463482.
- Effect of Isolated Fraction from Biophytum reinwardtii on Dexamethasone Induced Insulin Resistance in Rats
Abstract Views :74 |
PDF Views:0
Authors
Nagaraju Bandaru
1,
A. Narayana Rao
1,
Yasho Deepika
2,
Alekhya Ketha
3,
Daveedu Thathipudi
4,
N. Sri Laxmi
1
Affiliations
1 College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddesweram, Guntur - 522502, Andhra Pradesh, IN
2 Department of Pharmacy, Anurag University, Venkatapur, Ghatkesar, Hyderabad - 500088, Telangana, IN
3 Bharat Institute of Technology-Pharmacy, Mangalpally, Hyderabad - 501510, Telangana, IN
4 Department of Biotechnology, Vikarma Simhapuri University, Nellore – 524320, Andhra Pradesh, IN
1 College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddesweram, Guntur - 522502, Andhra Pradesh, IN
2 Department of Pharmacy, Anurag University, Venkatapur, Ghatkesar, Hyderabad - 500088, Telangana, IN
3 Bharat Institute of Technology-Pharmacy, Mangalpally, Hyderabad - 501510, Telangana, IN
4 Department of Biotechnology, Vikarma Simhapuri University, Nellore – 524320, Andhra Pradesh, IN
Source
Toxicology International (Formerly Indian Journal of Toxicology), Vol 30, No 1 (2023), Pagination: 19-27Abstract
The Fraction from Methanolic extract whole plant of Biophytum reinwardtii (HEMBR) is traditionally used in the treatment of diabetes. Rats were treated with a standardized dose of Dexamethasone for 14 days and the effect of HEMBR at the doses of 50 and 100 mg/kg, p.o. on plasma blood glucose level, serum triglyceride level, glucose uptake in skeletal muscle, levels of hepatic antioxidant enzymes (GSH, SOD and catalase), and body weight were observed. HEMBR showed a significant decrease in plasma glucose and serum triglyceride levels (p < 0.01) at the dose of 50 and 100 mg/kg, p.o. and also stimulated glucose uptake in skeletal muscle. The levels of antioxidant enzymes, GSH, SOD, and catalase were significantly increased (p < 0.01). Hence it can be concluded that Biophytum reinwardtii may prove to be effective in the treatment of Type-II Diabetes mellitus owing to its ability to decrease insulin resistance.Keywords
Antioxidants, Diabetes, Fraction, Insulin, ResistanceReferences
- Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration. 2010; 375:2215- 22. https://doi.org/10.1016/S0140-6736(10)60484-9 PMid:20609967
- Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990-2010: A systematic analysis. Lancet Global Health 2013; 1:e339-49. https://doi.org/10.1016/S2214- 109X(13)70113-X PMid:25104599
- USRDS Annual Data Report. Epidemiology of kid¬ney disease in the United States. United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2014. p. 188-210.
- Fowler MJ. Diabetes treatment, Part 2: Oral agents for glycemic management. Clin Diabetes. 2007; 25:131-4 https://doi.org/10.2337/diaclin.25.4.131
- Geer EB, Islam J, Buettner C. Mechanisms of glucocorti¬coid-induced insulin resistance: Focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am. 2014; 43:75-102. https://doi.org/10.1016/j. ecl.2013.10.005 PMid:24582093 PMCid:PMC3942672
- Brady VJ, Grimes D, Armstrong T, LoBiondo-Wood G. Management of steroid-induced hyperglycemia in hos¬pitalized patients with cancer: A review. Oncol Nurs Forum. 2014; 41:E355-65. https://doi.org/10.1188/14. ONF.E355-E365 PMid:25355031
- Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest. 1983; 72:1814-20. https://doi.org/10.1172/JCI111141 PMid:6355186 PMCid:PMC370470
- van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards the expansion of therapeutic options? Eur J Clin Invest. 2009; 39:81-93. https://doi.org/10.1111/j.1365- 2362.2008.02067.x PMid:19200161
- Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, et al. Dexamethasone-induced insulin resistance in 3T3L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduc¬tion. Diabetes. 2000; 49:1700-8. https://doi.org/10.2337/ diabetes.49.10.1700 PMid:11016454
- Nalini K, Karanth KS, Rao A, Aroor AR. Effects of Celastrus paniculatous on passive avoidance per-formance and biogenic amine turnover in albino rats. J Ethnopharmacol 1995; 47:1018. https://doi. org/10.1016/0378-8741(95)01264-E PMid:7500635
- Subha D, Geetha N. Evaluation of acute toxicity of the methanolic extract of Tanacetum parthenium L. in albino wistar rats. Journal of Scientific and Innovative Research. 2017; 6(3):113-5. https://doi.org/10.31254/ jsir.2017.6307
- Gholap S, Kar A. Gymnemic acids from Gymnema syl¬vestre potentially regulate dexamethasone-induced hyperglycemia in mice. Pharmaceutical Biology. 2005; 43:192-5. https://doi.org/10.1080/13880200590919564
- Ellaman GL. Tissue sulfhydryl group. Archives Biochemistry and Biophysiology. 1959; 6:70-7. https:// doi.org/10.1016/0003-9861(59)90090-6 PMid:13650640
- Mishra HP, Fridovich I. Role of superoxide anion in auto-oxidation of epinephrine and a simple assay for superoxide dismutase. Journal of Biological Chemistry. 1972; 247:3170-5. https://doi.org/10.1016/S0021- 9258(19)45228-9
- Bergmeyer H-U. Methods of Enzymatic Analysis. Chemic Academic Press Inc; 1974. p. 673-85.
- Sabu MC, Subburaju T. Effect of Cassia auriculata Linn. onserum glucose level, glucose utilization by isolated rat hemidia-phragm. Journal of Ethnopharmacology. 2002; 80:203-6. https://doi.org/10.1016/S0378- 8741(02)00026-0 PMid:12007712
- Harber RS, Weinstein SP. Role of glucose transporter in glucocorticoid induced insulin resistance GLUT4 isoform in rat skeletal muscle is not decreased by Dexamethasone. Diabetes. 1992; 41:728-35. https://doi. org/10.2337/diab.41.6.728
- Kim DS, Kim TW, Park IK, Kang JS, Om AS. Effect of chromium picolinate supplementation on insulin sensitivity, serum lipid, and body weight in dexametha¬sone-treated rats. Metabolism. 2002; 51:589-94. https:// doi.org/10.1053/meta.2002.31985 PMid:11979390
- Schmidt TJ, Miller-Diener A, Litwack G. Lapachone, a specific competitive inhibitor of ligand binding to the glucocorti-coid receptor. The Journal of Biological Chemistry. 1984; 259:9536-43. https://doi.org/10.1016/ S0021-9258(17)42733-5 PMid:6746659
- Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. Journal of Clinical Investigation. 2001; 108:635-6. https://doi.org/10.1172/JCI13727 PMid:11518739 PMCid:PMC209408